PHILADELPHIA--(BUSINESS WIRE)--AVAX Technologies, Inc. (OTCMarket:AVXT.OB) today announced that the Company, through its wholly owned subsidiary, Genopoeitic SAS, has received notification from the European Medicines Agency (EMEA) that it has been granted designation as a Small/Medium Enterprise (SME). The SME program, which was implemented in November 2005, is an initiative to assist small companies applying for approval of medicinal products with EMEA. In addition to financial benefits afforded the designation, through lowered or reduced fees, the designation offers participants access to scientific advice during the clinical development and application processes.
